Swedish joins EATRIS – Uppsala University is national node


After two years as observer Sweden – with national node at Uppsala University – joins EATRIS, the European Research Infrastructure for Translational Medicine, which has created a new arena for developing medical tools and treatments.

In Swedish Uppsala universitet blir svensk nod i EATRIS

Sweden joins EATRIS as the twelfth nation in the European Research Infrastructure for Translational Medicine. Uppsala University will function as Swedish node, and Mats Larhed, National Director and Professor of Medicinal Chemistry, describes an extensive interest in the opportunities to come.
– We have, on behalf of the Swedish Research Council, identified the needs of Swedish universities, biotech- and pharmaceutical companies, and the response has been very positive. The industry demands the academy's knowledge and resources, the researchers see important value in contributing their expertise. We have also initiated a major European co-project and the first signals indicate significant collaborative gains, says Mats Larhed.

Translational medicine aims at transferring new knowledge from basic research to patient-related healthcare, and with EATRIS, the EU sets new boundaries for accelerating the development of new drug treatments, diagnostic tools and related medical products.
– As pharmaceutical companies abandon early research in favor of later stages of development, society must make use of the ideas and knowledge that remain. As a member of EATRIS, Sweden will have access to an effective link between industry and academia, as well as an almost unique network of carefully selected partners in both Europe and other parts of the world, says Ulrika Bäckman, national coordinator with office at Uppsala Biomedical Center.

The node at Uppsala University has been structuring a national infrastructure for Swedish researchers and biomedical companies for two years. So far, five universities and the Uppsala Academic Hospital have joined, and many private companies express their wish for cooperation.
– We continuously receive scientifically challenging requests from both Swedish and European companies, and it is exactly in these complex projects EATRIS is a major force. Our central database includes information about all partners' knowledge and resources, which enables us to rapidly match every need with the most suitable executives and call for an initial meeting, says Ulrika Bäckman.

EATRIS works within five focus areas – Biomarkers, ATMP, Imaging & Tracing, Small molecules and Vaccine – and for Swedish universities, the membership opens an international window for collaboration, but also offers new opportunities for professional interaction across traditional boundaries.
– Sweden is definitely an attractive partner in EATRIS. We have many technically prominent platforms and well-developed biobanks, and for our researchers, EATRIS generates important areas to launch their expertise and to form the right groupings, such as applications for major international calls. The Swedish Research Council will finance our activities to 2020, but we look much further than that. Here are great values for everyone, says Mats Larhed.


  • The European Infrastructure for Translational Medicine (EATRIS) was founded in 2009 and fully operational in 2014. Sweden has participated as an observer since 2015 and becomes a full member in 2018.
  • EATRIS brings together twelve European countries and collaborates in the context of Translation Together with similar infrastructures in Australia, Canada and the United States.
  • In Sweden, Chalmers, Gothenburg University, Karolinska Institutet, KTH, Uppsala University and the Academic Hospital in EATRIS are participating. Lund University is expected to join shortly and negotiations are taking place with institutes and companies.

More information EATRIS Sweden

Contact: Ulrika Bäckman, National Coordinator
Contact: Mats Larhed, National Director

Magnus Alsne